Evidence map›Paper›PMID 39269657›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Survival impact of [

Alexandre Lugat, Nicolas Chouin, Florian Chocteau, Mathilde Esnault, Séverine Marionneau-Lambot, Sébastien Gouard, Éric Frampas, Alain Faivre-Chauvet, Mickaël Bourgeois, Alfred Morgenstern and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Alexandre LugatMedical Oncology Department, Nantes University Hospital, 44000, Nantes, France.ORCID 0000-0002-2278-0488
Nicolas ChouinNantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, 8 Quai Moncousu, BP70721, Cedex 1, 44007, Nantes, France.
Florian ChocteauNantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, 8 Quai Moncousu, BP70721, Cedex 1, 44007, Nantes, France.
Mathilde EsnaultNantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, 8 Quai Moncousu, BP70721, Cedex 1, 44007, Nantes, France.
Séverine Marionneau-LambotNantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, 8 Quai Moncousu, BP70721, Cedex 1, 44007, Nantes, France.
Sébastien GouardNantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, 8 Quai Moncousu, BP70721, Cedex 1, 44007, Nantes, France.
Éric FrampasNantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, 8 Quai Moncousu, BP70721, Cedex 1, 44007, Nantes, France.
Alain Faivre-ChauvetNuclear Medicine Department, Nantes University Hospital, 1, Place Alexis Ricordeau, 44000, Nantes, France.
Mickaël BourgeoisNuclear Medicine Department, Nantes University Hospital, 1, Place Alexis Ricordeau, 44000, Nantes, France.
Alfred MorgensternEuropean Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe, Germany.
Frank BruchertseiferEuropean Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe, Germany.
Michel ChérelNantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, 8 Quai Moncousu, BP70721, Cedex 1, 44007, Nantes, France.
Françoise Kraeber-Bodéré *Nuclear Medicine Department, Nantes University Hospital, 1, Place Alexis Ricordeau, 44000, Nantes, France.
Catherine Ansquer *Nuclear Medicine Department, Nantes University Hospital, 1, Place Alexis Ricordeau, 44000, Nantes, France.
Joëlle Gaschet *Nantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, 8 Quai Moncousu, BP70721, Cedex 1, 44007, Nantes, France. joelle.gaschet@univ-nantes.fr.

Funding

Fondation pour la recherche médicale FDM202006011156Labex Iron ANR-11-LABX-18-01RHU OPERANDI ANR-21-RHUS-0012SIRIC ILIAD INCa-DGOS-INSERM/ITMO Cancer_18011
6 · The paper itself

Abstract

Although peptide radionuclide therapy (PRRT) using a somatostatin analog (SSA) radiolabeled with a beta- emitter: [

methodsA mouse model of liver metastases of pancreatic NETs was developed by intraportal injection of AR42J cells and explored using [

resultsLiver tumors showed a high uptake of [

conclusion[

Indexed as

Alpha ParticlesLiver NeoplasmsNeuroendocrine TumorsOctreotideOrganometallic CompoundsPancreatic NeoplasmsActiniumAnimalsCell Line, TumorDisease Models, AnimalFemaleMiceRadiopharmaceuticalsTissue DistributionActiniumActinium-225OctreotideOrganometallic CompoundsRadiopharmaceuticalsActinium-225Neuroendocrine tumorPET/MRISomatostatin analogsTargeted alpha therapy

Identifiers

PMID39269657

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.